

REMARKS

Claims 1-16 are pending in the present application.

The Examiner has required a further election in the present application between:

A. The 16-position hydroxylating enzymatic activity for macrolide compound 11107B, selected from the group consisting of:


1. A continuous nucleotide sequence from base 1322 to base 2548 of SEQ ID NO: 1;
 2. A continuous nucleotide sequence from the base 420 to 1604 of SEQ ID NO: 2;
 3. A continuous nucleotide sequence from the base 172 to base 1383 of SEQ ID NO: 3;
 4. A variant of the sequences in 1-3 above, that hybridizes to the above sequences under stringent conditions, and encodes a protein having hydroxylating enzymatic activity for macrolide compound 11107B;
 5. A degenerate variant of one of the sequences in 1-3 above, and
- B. The 16-position hydroxylating enzymatic activity is for macrolide compound 11107D.

For the purpose of examination of the present application, Applicants elect, without traverse, A.(1.) – A continuous nucleotide sequence from base 1322 to base 2548 of SEQ ID NO: 1.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: October 22, 2008

Respectfully submitted,

By  #32,881
Marc S. Weiner
Registration No.: 32,181
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicants